(S)-1-phenyl-2-pyrrolidin-1-yl-ethylamine dihydrochloride | 1609680-93-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-1-phenyl-2-pyrrolidin-1-yl-ethylamine dihydrochloride
• 英文别名: (1S)-1-phenyl-2-pyrrolidin-1-ylethanamine dihydrochloride；(S)-1-phenyl-2-(pyrrolidin-1-yl)ethan-1-amine hydrochloride；(1S)-1-phenyl-2-pyrrolidin-1-ylethanamine;hydrochloride
• CAS: 1609680-93-4
• 化学式: C₁₂H₁₈N₂*2ClH
• 分子量: 263.21
• InChiKey: GWJSDZLXRREOIA-UTONKHPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(6-fluoropyridin-2-yl)benzenesulfonamide 、 (S)-1-phenyl-2-pyrrolidin-1-yl-ethylamine dihydrochloride 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 18.0h， 以49%的产率得到(S)-5-chloro-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(6-fluoropyridin-2-yl)-4-((1-phenyl-2-(pyrrolidin-1-yl)ethyl)amino)benzenesulfonamide
  参考文献：
  名称：

  BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

  摘要：

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗与电压门控钠通道相关的疾病或症状，如癫痫和/或癫痫发作障碍。

  公开号：

  US20180162868A1

文献信息

• Benzenesulfonamide compouds and their use as therapeutic agents
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US11174268B2

  公开（公告）日：2021-11-16

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

  本发明涉及苯磺酰胺化合物，作为其立体异构体、对映体、同系物或其混合物；或其药学上可接受的盐、溶液剂或原药，用于治疗与电压门控钠通道相关的疾病或病症，如癫痫和/或癫痫发作性疾病。
• Thieno[3,2-c]pyrazoles: A novel class of Aurora inhibitors with favorable antitumor activity
  作者：Simona Bindi、Daniele Fancelli、Cristina Alli、Daniela Berta、Jay A. Bertrand、Alexander D. Cameron、Paolo Cappella、Patrizia Carpinelli、Giovanni Cervi、Valter Croci、Matteo D’Anello、Barbara Forte、M. Laura Giorgini、Aurelio Marsiglio、Juergen Moll、Enrico Pesenti、Valeria Pittalà、Maurizio Pulici、Federico Riccardi-Sirtori、Fulvia Roletto、Chiara Soncini、Paola Storici、Mario Varasi、Daniele Volpi、Paola Zugnoni、Paola Vianello

  DOI：10.1016/j.bmc.2010.07.048

  日期：2010.10

  A novel series of 3-amino-1H-thieno[3,2-c]pyrazole derivatives demonstrating high potency in inhibiting Aurora kinases was developed. Here we describe the synthesis and a preliminary structure-activity relationship, which led to the discovery of a representative compound (38), which showed low nanomolar inhibitory activity in the anti-proliferation assay and was able to block the cell cycle in HCT-116 cell line. This compound demonstrated favorable pharmacokinetic properties and good efficacy in the HL-60 xenograft tumor model.
• [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS DE BENZÈNESULFONAMIDE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2018106284A1

  公开（公告）日：2018-06-14

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.